We have probably all heard terms like “liquid biopsy” and “genetic screening” and “cell-free” DNA analysis over the past few years. These are all terms related to the use of genetic and genomic information to “personalize” cancer diagnosis and its management. And they are potentially a huge big deal. But, … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: analysis, cancer, detection, DNA, Management, monitoring, risk | 4 Comments »
A new paper in a new journal argues that all men diagnosed with advanced forms of prostate cancer should now, routinely, be undergoing tumor and germline DNA profiling … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: analysis, genetic, genomic, targeted, testing, therapy | 2 Comments »
So the other morning your sitemaster learned that a relatively new FirstWord Therapy Report had come out that dealt with future use of biopharmaceuticals in the treatment of progressive and advanced prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: analysis, development, drug, information, new, ongoing | 4 Comments »
A new study, to published shortly on-line in Cancer, suggests that significant alterations to the “copy numbers” of the PTEN and MYC genes in men with prostate cancer are strongly associated with risk for prostate cancer-specific mortality. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: alteration, analysis, copy number, gene, mortality, MYC, PTEN, risk | 3 Comments »
For those who are really “into” the probabilistic statistics of prostate cancer decision analysis, we recommend a recent article in the journal Medical Decision-Making. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: analysis, decision, Markov, model, PSA, screening | 7 Comments »
